CytoSPAR

CytoSPAR is a private U.S. diagnostics and biomolecular engineering company developing rapid infectious disease testing technologies. Its core SPAR platform is a programmable cell-based detection system designed to identify bacteria, viruses, proteins, and antibodies, and the company also markets blAST, a rapid phenotypic antimicrobial susceptibility testing assay run directly from urine samples. CytoSPAR positions its technology as enabling actionable results within hours or less, with applications across hospital, emergency, veterinary, and broader pathogen-detection settings. Based on publicly available materials, the company appears focused on diagnostic products rather than therapeutic drug development. The blAST assay is described by the company as research-use only and not FDA cleared or approved for diagnostic procedures.